Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Trevi Therapeutics
3103
Trevi Therapeutics
Technology
Biotechnology
Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
Suggest edits
Founded
2011
Raised
$98.1M
Follow us
Companies in the same industry
DNAnexus
Blue Belt Technologies
Scripps Research
Seres Therapeutics
EarlySense
Ortho Kinematics
Myomo
Cardax
RaNA Therapeutics
Editas Medicine
Alexa global traffic share
Twitter followers
Overview
Funding
4
Add info
Add round
20 Jul
2017
$50,500,000
Venture capital (Series C)
NEA
,
Omega Funds
,
TPG Biotechnology Partners
,
+2
NEA leads $50.5 mln Series C round in Trevi Therapeutics
PE HUB
08 Jan
2015
$15,000,000
Debt financing
Square 1 Bank
,
Solar capital
Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor
abladvisor
06 Nov
2014
$26,000,000
Venture capital (Series B)
TPG Biotech
18 Dec
2012
$6,564,102
Venture capital